Survival control of malignant lymphocytes by anti-apoptotic MCL-1

被引：34
作者：
Fernandez-Marrero, Y. [1 ]
Spinner, S. [2 ]
Kaufmann, T. [1 ]
Jost, P. J. [2 ]
机构：
[1] Univ Bern, Fac Med, Inst Pharmacol, Bern, Switzerland
[2] Tech Univ Munich, Klinikum Rechts Isar, Med Dept Hematol & Oncol 3, Ismaningerstr 22, D-81675 Munich, Germany
来源：
LEUKEMIA | 2016年 / 30卷 / 11期
基金：
瑞士国家科学基金会;
关键词：
T-CELL LYMPHOMA; BCL-2 FAMILY PROTEINS; NON-HODGKINS-LYMPHOMA; STRUCTURE-GUIDED DESIGN; GENOME-WIDE ANALYSIS; DOWN-REGULATION; IN-VITRO; B-CELLS; ANAPLASTIC LYMPHOMA; SIGNALING PATHWAY;
D O I：
10.1038/leu.2016.213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Programmed apoptotic cell death is critical to maintain tissue homeostasis and cellular integrity in the lymphatic system. Accordingly, the evasion of apoptosis is a critical milestone for the transformation of lymphocytes on their way to becoming overt lymphomas. The anti-apoptotic BCL-2 family proteins are pivotal regulators of the mitochondrial apoptotic pathway and genetic aberrations in these genes are associated with lymphomagenesis and chemotherapeutic resistance. Pharmacological targeting of BCL-2 is highly effective in certain indolent B-cell lymphomas; however, recent evidence highlights a critical role for the BCL-2 family member MCL-1 in several lymphoma subtypes. MCL-1 is recurrently highly expressed in various kinds of cancer including non-Hodgkin's lymphoma of B-and T-cell origin. Moreover, both indolent and aggressive forms of lymphoma require MCL-1 for lymphomagenesis and for their continued survival. This review summarizes the role of MCL-1 in B-and T-cell lymphoma and discusses its potential as a therapeutic target.
引用
收藏
页码：2152 / 2159
页数：8
相关论文
共 100 条
  • [1] Bcl-2 family of proteins in indolent B-cell non-Hodgkin's lymphoma: Study of 116 cases
    Agarwal, B
    Naresh, KN
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2002, 70 (04) : 278 - 282
  • [2] The landscape of somatic copy-number alteration across human cancers
    Beroukhim, Rameen
    Mermel, Craig H.
    Porter, Dale
    Wei, Guo
    Raychaudhuri, Soumya
    Donovan, Jerry
    Barretina, Jordi
    Boehm, Jesse S.
    Dobson, Jennifer
    Urashima, Mitsuyoshi
    Mc Henry, Kevin T.
    Pinchback, Reid M.
    Ligon, Azra H.
    Cho, Yoon-Jae
    Haery, Leila
    Greulich, Heidi
    Reich, Michael
    Winckler, Wendy
    Lawrence, Michael S.
    Weir, Barbara A.
    Tanaka, Kumiko E.
    Chiang, Derek Y.
    Bass, Adam J.
    Loo, Alice
    Hoffman, Carter
    Prensner, John
    Liefeld, Ted
    Gao, Qing
    Yecies, Derek
    Signoretti, Sabina
    Maher, Elizabeth
    Kaye, Frederic J.
    Sasaki, Hidefumi
    Tepper, Joel E.
    Fletcher, Jonathan A.
    Tabernero, Josep
    Baselga, Jose
    Tsao, Ming-Sound
    Demichelis, Francesca
    Rubin, Mark A.
    Janne, Pasi A.
    Daly, Mark J.
    Nucera, Carmelo
    Levine, Ross L.
    Ebert, Benjamin L.
    Gabriel, Stacey
    Rustgi, Anil K.
    Antonescu, Cristina R.
    Ladanyi, Marc
    Letai, Anthony
    [J]. NATURE, 2010, 463 (7283) : 899 - 905
  • [3] New dimension in therapeutic targeting of BCL-2 family proteins
    Besbes, Samaher
    Mirshahi, Massoud
    Pocard, Marc
    Billard, Christian
    [J]. ONCOTARGET, 2015, 6 (15) : 12862 - 12871
  • [4] Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
    Bruncko, Milan
    Wang, Le
    Sheppard, George S.
    Phillips, Darren C.
    Tahir, Stephen K.
    Xue, John
    Erickson, Scott
    Fidanze, Steve
    Fry, Elizabeth
    Hasvold, Lisa
    Jenkins, Gary J.
    Jin, Sha
    Judge, Russell A.
    Kovar, Peter J.
    Madar, David
    Nimmer, Paul
    Park, Chang
    Petros, Andrew M.
    Rosenberg, Saul H.
    Smith, Morey L.
    Song, Xiaohong
    Sun, Chaohong
    Tao, Zhi-Fu
    Wang, Xilu
    Xiao, Yu
    Zhang, Haichao
    Tse, Chris
    Leverson, Joel D.
    Elmore, Steven W.
    Souers, Andrew J.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (05) : 2180 - 2194
  • [5] Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance
    Campbell, Kirsteen J.
    Bath, Mary L.
    Turner, Marian L.
    Vandenberg, Cassandra J.
    Bouillet, Philippe
    Metcalf, Donald
    Scott, Clare L.
    Cory, Suzanne
    [J]. BLOOD, 2010, 116 (17) : 3197 - 3207
  • [6] Parkin Sensitizes toward Apoptosis Induced by Mitochondrial Depolarization through Promoting Degradation of Mcl-1
    Carroll, Richard G.
    Hollville, Emilie
    Martin, Seamus J.
    [J]. CELL REPORTS, 2014, 9 (04): : 1538 - 1553
  • [7] Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F
    Cencic, Regina
    Hall, David R.
    Robert, Francis
    Du, Yuhong
    Min, Jaeki
    Li, Lian
    Qui, Min
    Lewis, Iestyn
    Kurtkaya, Serdar
    Dingledine, Ray
    Fu, Haian
    Kozakov, Dima
    Vajda, Sandor
    Pelletier, Jerry
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (03) : 1046 - 1051
  • [8] Interleukin-7 promotes the survival of human CD4+effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway
    Chetoui, Nizar
    Boisvert, Marc
    Gendron, Steve
    Aoudjit, Fawzi
    [J]. IMMUNOLOGY, 2010, 130 (03) : 418 - 426
  • [9] MCL-1 expression in B-cell non-Hodgkin's lymphomas
    Cho-Vega, JH
    Rassidakis, GZ
    Admirand, JH
    Oyarzo, M
    Ramalingam, P
    Paraguya, A
    McDonnell, TJ
    Amin, HM
    Medeiros, LJ
    [J]. HUMAN PATHOLOGY, 2004, 35 (09) : 1095 - 1100
  • [10] MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
    Choudhary, G. S.
    Al-Harbi, S.
    Mazumder, S.
    Hill, B. T.
    Smith, M. R.
    Bodo, J.
    Hsi, E. D.
    Almasan, A.
    [J]. CELL DEATH & DISEASE, 2015, 6 : e1593 - e1593
12345678910